Cytokine Profile in the Upper Airways of Patients With N-ERD Obtained via a Minimally Invasive Method

Documenti analoghi

• Correction: The relationship of chemokine levels and the type of symptoms caused by NSAIDs or alcohol in patients with NSAIDs-exacerbated respiratory disease
  di: Karolina Frachowicz-Guerreiro, et al.
  Pubblicazione: (2026-06-01)
• Factors affecting upper airway control of NSAID‐exacerbated respiratory disease: A real‐world study of 167 patients
  di: Annina Lyly, et al.
  Pubblicazione: (2021-03-01)
• Biologic therapies targeting type 2 inflammation in NSAID−exacerbated respiratory disease
  di: Piotr Szatkowski, et al.
  Pubblicazione: (2026-07-01)
• Dupilumab treatment has no effect on the nasal microbiome in patients with NSAID-exacerbated respiratory disease: a longitudinal pilot study
  di: Tina Bartosik, et al.
  Pubblicazione: (2025-05-01)
• Critical pathomechanisms of NSAID-exacerbated respiratory disease (N-ERD) clarified by treatment with omalizumab, an anti-IgE antibody
  di: Hiroaki Hayashi, et al.
  Pubblicazione: (2025-01-01)